Commercially Available Cannabis Products for Immune Support

Description

This study will be a prospective observation of the use of commercially available hemp and cannabis products marketed for immune support.

Conditions

Influenza, COVID-19, Common Cold

Talk to us

Study Overview

On this page

Study Details

Study overview

This study will be a prospective observation of the use of commercially available hemp and cannabis products marketed for immune support.

Commercially Available Cannabis (Hemp) Products for Immune Support: A Prospective Observational Study to Evaluate Safety and Effects

Commercially Available Cannabis Products for Immune Support

Condition
Influenza
Intervention / Treatment

-

Contacts and Locations

Bryn Mawr

Center for Interventional Pain and Spine, Bryn Mawr, Pennsylvania, United States, 19010

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. 18 years of age or older
  • 2. Able to read and write in English
  • 3. Active participants in the Pennsylvania medical marijuana program (for cannabis product users)
  • 4. Currently experiencing one or more of the following symptoms due to an acute illness:
  • 1. Fever or chills
  • 2. Cough
  • 3. Fatigue
  • 4. Muscle or body aches
  • 5. Headache
  • 6. Sore throat
  • 7. Congestion or runny nose
  • 8. Nausea or Vomiting
  • 9. Diarrhea
  • 5. Agrees to consume their chosen hemp or cannabis product (for the cannabis arm) and to not use a different hemp or cannabis product through the duration of the study
  • 6. Agrees to continue to abstain from using hemp or cannabis (for the non-cannabis/hemp using arm)
  • 7. Must have smart phone or email and access to the internet
  • 8. Be able to comply with study requirements including baseline, completion of electronic questionnaires, and study timeline parameters.
  • 1. Women who are pregnant, breastfeeding, or planning to become pregnant.
  • 2. Known allergy to any compounds in hemp or cannabis.
  • 3. Endorses suicidal intent
  • 4. Immunocompromised individuals
  • 5. Unwilling or unable to comply with study procedures
  • 6. Terminal Illness with life expectancy less than 1 year

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Center For Interventional Pain and Spine,

Philip Kim, MD, PRINCIPAL_INVESTIGATOR, Center For Interventional Pain and Spine

Study Record Dates

2024-12-01